Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,233,276
  • Shares Outstanding, K 50,281
  • Annual Sales, $ 3,340 K
  • Annual Income, $ -213,260 K
  • 60-Month Beta 1.85
  • Price/Sales 3,392.27
  • Price/Cash Flow N/A
  • Price/Book 18.34
Trade MRTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -2.28
  • Number of Estimates 8
  • High Estimate -2.03
  • Low Estimate -2.98
  • Prior Year -1.83
  • Growth Rate Est. (year over year) -24.59%

Price Performance

See More
Period Period Low Period High Performance
1-Month
187.01 +20.56%
on 10/27/20
240.58 -6.28%
on 11/04/20
+45.26 (+25.12%)
since 10/23/20
3-Month
130.60 +72.63%
on 09/11/20
240.58 -6.28%
on 11/04/20
+76.87 (+51.73%)
since 08/25/20
52-Week
66.01 +241.55%
on 03/18/20
240.58 -6.28%
on 11/04/20
+129.90 (+135.94%)
since 11/25/19

Most Recent Stories

More News
Mirati Therapeutics To Participate In The 2020 Evercore ISI HealthCONx Conference

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 2020 Evercore ISI HealthCONx Conference...

MRTX : 225.46 (+0.92%)
Look for Shares of Mirati Therapeut to Potentially Rebound after Yesterday's 1.35% Sell Off

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $218.50 to a high of $227.15. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of...

MRTX : 225.46 (+0.92%)
OncoMyx Therapeutics Appoints Dr. Charles Baum Chairperson of Board of Directors

OncoMyx Therapeutics, a privately held oncolytic immunotherapy company, today announced the appointment of Charles (Chuck) M. Baum, M.D., Ph.D., as chairperson of the company's board of directors. Dr....

MRTX : 225.46 (+0.92%)
Mirati Therapeutics To Participate In The 29th Annual Credit Suisse Virtual Healthcare Conference

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced they will participate in a fireside chat at the 29th Annual Credit Suisse Virtual...

MRTX : 225.46 (+0.92%)
Mirati (MRTX) Reports Q3 Loss, Tops Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 3.92% and 1580.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

MRTX : 225.46 (+0.92%)
Mirati: 3Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Wednesday reported a loss of $87.3 million in its third quarter.

MRTX : 225.46 (+0.92%)
Mirati Therapeutics Reports Third Quarter 2020 Financial Results And Recent Business Highlights

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended and recent business highlights.

MRTX : 225.46 (+0.92%)
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

, /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 4,985,706 shares of its common stock at a public offering...

MRTX : 225.46 (+0.92%)
Why Mirati Therapeutics (MRTX) Might Surprise This Earnings Season

Mirati Therapeutics (MRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MRTX : 225.46 (+0.92%)
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock

, /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the pricing of an underwritten public offering of 4,335,397 shares of its common stock at a price to the public of per share,...

MRTX : 225.46 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

See More

Key Turning Points

2nd Resistance Point 229.63
1st Resistance Point 227.55
Last Price 225.46
1st Support Level 223.07
2nd Support Level 220.67

See More

52-Week High 240.58
Last Price 225.46
Fibonacci 61.8% 173.89
Fibonacci 50% 153.29
Fibonacci 38.2% 132.70
52-Week Low 66.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar